During the Forbes Healthcare Summit in Douglas Ingram, Sarpta Theraputics Inc., New York, US, on Tuesday, December 5, 2023 during the Forbes Healthcare Summit in New York, US.
Michael Nagle | Bloomberg | Getty images
Share of Sarpta theraputics On Friday, the future of its approved gene therapy treatment appeared at risk as a decline of over 30%.
The food and drug administration will request that the company voluntarily prevents all the shipments of treatment, elevidis, a person acquainted with the case told CNBC.
Sarpta told CNBC that it had not heard from FDA.
Separately, FDA Commissioner Marti Makari Told Bloomberg News The agency is considering whether the company’s gene therapy should stay on the market.
The FDA is investigating two patients tied to Alidis. The company also reported the third death related to a separate experimental gene therapy.
The company’s stock has now fallen more than 87% this year.
– CNBC’s Angelica Pables contributed to this report
This story is developing. Please check back for updates.
